- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Despite clinical studies that reveal low accuracy of these devices, the Oxi Metrix III Opti Cath (Abbott Critical Care Systems) is utilized for continuous assessment of venous saturation in a range of applications, including extracorporeal membrane oxygenation (ECMO).
The CDI Blood Parameter Monitoring System 500 (Terumo) is an inline blood gas monitoring equipment used to continually measure oxygen saturation, blood gasses, potassium, and bicarbonate during cardiopulmonary bypass treatments.
The goal of this study was to evaluate the Opti Cath and the CDI 500 in trending venous blood saturation during an ECMO simulation. A silicone rubber membrane oxygenator and a stainless steel heat exchanger were utilized to build an ECMO simulation circuit, and a typical venous reservoir bag was employed to simulate the patient.
The CDI and the Opticath were linked together in a shunt that began just before the oxygenator and returned flow to the venous line. To imitate normal venous blood under ECMO conditions, the circuit was primed with fresh porcine blood and conditioned with CO2.
Following an initial calibration process, samples were taken and analyzed by an AVL Opti CCA (Roche/Osmatic) every hour for days, with each device calibrated at sample intervals.
A least squares regression line was created after plotting the data. The average inaccuracy of the CDI and Opti Cath for venous saturation. A correlation coefficient was obtained from the CDI and AVL CCA analyzer correlation analysis.
The Global Blood Parameter Monitoring System Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, announced today that the FDA has granted 510(k) clearance for the CDI Blood Parameter Monitoring System 550, adding real-time monitoring of oxygen delivery as one of critical blood parameters.
DO2, or oxygen delivery, is a measure of the quantity of oxygen provided to a patient during cardiopulmonary bypass. Acute Kidney Injury, a major consequence of cardiac surgery, has been demonstrated to be reduced when DO2 levels are carefully monitored.
Terumo's CDI Systems have been the most trusted and widely used continuous in-line blood gas monitors for vital blood parameters for many years, and they are still developing monitoring technologies for the cardiac OR - and beyond - that will enhance patient outcomes.
Terumo Cardiovascular Group is a worldwide leader in cardiovascular surgical technology. Continuous in-line monitoring is a vital component of perfusion safety during cardiopulmonary bypass surgery.
It promptly informs doctors of changes in patient status and provides crucial parameter information to assist clinicians in managing perfusion instances.
pH, pCO2, pO2, K+, temperature, SO2, hematocrit, hemoglobin, base excess, bicarbonate, oxygen consumption, and oxygen delivery are the 12 essential parameters measured or calculated by the new CDI System 550.
The next-generation CDI System 550, built on an industry-standard platform, has market-leading optical fluorescence technology, a high-visibility LCD screen, enhanced probe design, and IEC 60601-1 3rd Edition compliance.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.